Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gilead seeking to accelerate, maximize global access to remdesivir
May 05, 2020 10:42 PM ETGilead Sciences, Inc. (GILD)49 Comments
Gilead Sciences (NASDAQ:GILD) says it is in talks with "leading chemical and pharmaceutical companies" to expand manufacturing of its remdesivir COVID-19 treatment to ensure wider access to the drug in Europe, Asia and the developing world through at least 2022.
Gilead also is negotiating long-term voluntary licenses with several generic drugmakers in India and Pakistan to produce remdesivir for developing markets, as well as about how to license the drug in those markets.
The company also says it is in advanced talks with UNICEF to deliver remdesivir using the agency's distribution networks.
Moderna (NASDAQ:MRNA) Inc and Swiss contract drugmaker Lonza Group AG said on Friday they would accelerate the manufacturing of the U.S. drug developer's potential coronavirus vaccine.
The announcement comes at a time when drugmakers are pausing clinical trials for other disease areas as they focus on testing potential treatments for the coronavirus.
The experimental vaccine, mRNA-1273, is being tested in early-stage trial by the U.S. National Institutes of Health, with Moderna expecting to begin mid-stage trial in the second quarter.
Under the 10-year collaboration agreement, the companies aim to manufacture up to a billion doses per year as technology transfer is expected to begin in June, and the first batches of the vaccine are expected to be manufactured in Lonza U.S. in July.
"Over time, the parties intend to establish additional production suites across Lonza's worldwide facilities, ultimately allowing for the manufacture of material equivalent to up to 1 billion doses of mRNA-1273 per year for use worldwide", the statement added.
The disease, which infected more than 3.2 million people worldwide and killed around 232,000, set off a race among drugmakers to find an antidote.
Earlier this month, Moderna got a $483 million funding from a U.S. government agency to accelerate its COVID-19 vaccine development.
Separately, Basel-based Lonza's pharmaceuticals, biotech and nutrition business has received more than 40 enquiries regarding projects relating to COVID-19, the company said earlier in April.
Let’s not forget the potential here$$$$$$$
After getting positive data for its antiviral remdesivir in patients with COVID-19 and the Food and Drug Administration's authorization to use the drug last week, Gilead Sciences (NASDAQ:GILD) is turning its sights on making sure the drug is available globally.
On Tuesday, the biotech announced plans to increase the manufacturing of remdesivir, a drug that is quite hard to make and requires scarce raw materials that need to be produced separately.
Gilead is in discussions with other manufacturers that may be able to produce the drug for Europe, Asia, and the developing world through at least 2022. The company is also negotiating long-term voluntary licenses with multiple generic-drug makers in India and Pakistan, which would produce remdesivir for developing countries.
On the patent front, the company is working the Medicines Patent Pool, a United Nations-backed public health organization that acts as an intermediary between branded-drug companies and generic-drug companies to provide drugs to developing countries. Gilead has previously worked with Medicines Patent Pool to bring its HIV drugs to developing countries.
To get the drugs to the countries in need, Gilead is in discussions with UNICEF to hopefully use its distribution networks in low- and middle-income countries.
12:31 PM ET: Remdesivir Looks Set for Japan Approval Gilead Sciences (NASDAQ:GILD)' antiviral drug remdesivir may be approved in Japan for domestic COVID-19 patients when the health ministry’s review board is held on Thursday, Japanese Health Minister Katsunobu Kato said
TRUE DD HERE Shorty.... Incase you didn’t know rookie, Norwegian Cruise is the one hurting. Probably had better luck shorting them.
The Carnival Corporation, the giant cruise company widely criticized for its handling of the coronavirus pandemic, announced on Monday that some of its ships may begin sailing again as soon as August.
For months, lawmakers and epidemiologists have blamed Carnival for failing to contain outbreaks on its ships and spreading the virus across the world. Its response to the pandemic is the subject of a criminal investigation by the Australian police and a congressional investigation in the United States.
Despite that growing scrutiny, the company’s flagship cruise line said that eight of its ships could begin sailing on Aug. 1, about a week after a government order banning cruises in the United States is set to expire. Those ships, part of the Carnival Cruise Line brand, are scheduled to depart from ports in Galveston, Texas, Miami and Port Canaveral, Fla.
It would be only a partial reopening, and the timing could change as the company devises new safety protocols for its cruises. The eight ships that are slated to return to service are a small portion of the Carnival Corporation’s fleet of 105 vessels. Carnival Cruise Line said voyages on several of its other ships would be canceled through the beginning of October.
Great sell today $$$$$$$ Looking for another entry point myself!!!!
Bloomberg) -- Credit Suisse (SIX:CSGN) Group AG is doubling down on an oil trade linked to a fund at the epicenter of the historic price crash.
The Swiss bank is cashing in on the infamy of the U.S. Oil Fund LP, known as USO (NYSE:USO). It’s issuing fresh shares in a note that lets clients bet the $3.5 billion product will see calmer days after its near 80% plunge this year.
Using what’s known as a covered-call strategy, the X-Links Crude Oil Shares Covered Call exchange-traded note, ticker USOI, is structured to outperform if USO stays locked in sideways trading. A prospectus published last week showed the bank is adding 2.2 million shares, worth $54 million.
The world’s largest oil ETF captured headlines last month after retail investors got burned with ill-timed bets on a crude rebound. Amid negative prices, USO was forced to re-tool its methodology and took other extraordinary steps to prevent shuttering.
Now as the dust settles, Credit Suisse reckons it can tap fresh demand for traders seeking steady income from investing in oil futures.
Despite this week’s bounce in crude prices, oil looks stuck in a quagmire of weak demand and oversupply. Meanwhile USO’s issuer has upended how it tracks the commodity -- potentially capping both its gains when front-month oil futures rise and price swings going forward.
All of that looks set to boost the Credit Suisse strategy.
“USO implied volatility is obviously quite high, for good reason,” said Benn Eifert, chief investment officer at QVR Advisors. “But USO methodology changes have stabilized it somewhat, reduced left tail risk and reduced the volatility it should experience.”
Income Hunt
The Credit Suisse product holds shares of USO while simultaneously writing call options. The premium generated from selling those contracts is designed to provide a steady income. Since its 2017 inception, it’s outperformed its bigger sibling by around 19% on a total return basis.
The strategy isn’t without its risks. Like all covered-call products, it will underperform if USO goes on a tear. Also, if implied volatility of the ETF drops, it will earn less premium from selling the options contracts, hitting its dividend.
A spokesman for Credit Suisse declined to comment.
As investor interest in USO drops off in the wake of the tumult, the Swiss bank may be betting that investors will flock to its note as a viable alternative. Recent data from online trading platform Robinhood shows a drop in customers holding the beleaguered fund.
“The retail interest in USO has finally started to fade,” said Ole Hansen of Saxo Bank.
©2020 Bloomberg L.P.
Tough day for them for sure!!!!!!!!
U heard wrong, better read up on them.
Very soon, most are patiently waiting as I am... Lots of great DD here from most!!!!!
Let’s see how the day range goes!!!!! GLTA except Shorty $$$$$$
Most are shorting the ETFs... Best advice,,,, Do your own DD!!!! Best of trades to all except Shorty!!!!
Welcome back..... Nice re entry point!!!! With the potential of sailing in August,,,,, Things could turn for the best$$$$$$ GLTA expect Shorty
It’s the million dollar question for sure... Green portfolio sure is nice$$$$$$ Can’t blame anyone for taking profits. GLTA here except Shorty!!!!!
If your holding for long I’d say you’re good!!!!! Congrats $$$$$$$$
Hahahahaha, I’m trying to figure out where to put my gas cans that are filled!!!!!! Prices are too good to be true right now. My lawnmower is running on 93 not 87!!!!!!
GLTA here
By C Nivedita and Shreyashi Sanyal
April 29 (Reuters) - Wall Street jumped on Wednesday as Gilead Sciences gave an encouraging update on a potential COVID-19 treatment and upbeat earnings from Google-parent Alphabet boosted shares of other technology and internet giants.
Gilead rose 4.8% after the drugmaker said its experimental antiviral drug remdesivir helped improve symptoms for COVID-19 patients who were given the drug early.
"The news on Gilead is really powering the market," said Linda Duessel, senior equity strategist at Federated Hermes in Pittsburgh, Pennsylvania.
"While we wait for a vaccine, we are looking out for anything that will help us get back into society, and we're all hanging on this data on a day-by-day basis."
The three main indexes have recovered 30% from their mid-March lows, boosted by aggressive stimulus efforts and, more recently, on hopes of an economic revival as many U.S. states begin to relax lockdown measures.
Growth stocks such Facebook Inc, Apple Inc, Amazon.com Inc and Netflix Inc gained between 2% and 6%, while Alphabet Inc surged 8.6% as its quarterly report showed Google ad sales steadied in April.
The S&P 500 communication services sector index jumped 4.6%, the most among the 11 major sub-indexes.
Boeing Co reported a loss for the second straight quarter, but its shares rose 3.7% after the planemaker said it would cut jobs and try to boost liquidity.
Analysts foresee a sharper decline in second-quarter earnings, with companies listed on the S&P 500 expected to record a 35.1% decline in profits following a 15% drop in the first quarter, according to Refinitiv data.
Meanwhile, markets shrugged off data that showed the U.S. economy contracted in the first quarter at its sharpest pace since the Great Recession, ending the longest expansion in history.
"The economic data is backward-looking and markets will continue to be forward-looking," said Chris Zaccarelli, chief investment officer at Independent Advisor Alliance in Charlotte, NC.
Markets are trying to anticipate a resumption of economic activity in the short run and a vaccine in the medium term, he said.
At 10:18 a.m. ET the Dow Jones Industrial Average was up 422.64 points, or 1.75%, at 24,524.19, the S&P 500 was up 58.81 points, or 2.05%, at 2,922.20 and the Nasdaq Composite was up 233.27 points, or 2.71%, at 8,841.01.
General Electric Co fell 1% after its industrial businesses took a $1 billion hit to cash flow in the first quarter and it warned the damage would worsen in the next.
All eyes will be on the policy statement by the Federal Reserve at the end of its two-day meeting at 2 p.m. EDT (1800 GMT). The policymakers are expected to keep their promise to do whatever it takes to support the world's largest economy.
Advancing issues outnumbered decliners by a 6.70-to-1 ratio on the NYSE and a 4.25-to-1 ratio on the Nasdaq.
The S&P index recorded two new 52-week highs and no new lows, while the Nasdaq recorded 26 new highs and no new lows. (Reporting by C Nivedita Shreyashi Sanyal and Sruthi Shankar in Bengaluru; Editing by Bernard Orr and Arun Koyyur)
Some positive vibes for you OLD SCHOOL!!!!!!!!!
Who needs a bailout on days like today $$$$$$$$$ Next leg up and HOLDING!!!!!!!
7 printing $$$$$$$$
Better do some research my friend. Saudi investment firm bought there debt. They won’t need to travel for a year!!!!!!! Best thing to do is buy and hold for the long haul.... been here since 7s ..... Ain’t flipping for beer money. Plenty of room to run
Loving the vibes!!!!! Just another step in the right direction. Patients is key. Great start to the day regardless!!!!
6.50 and holding,,,, looking promising here today $$$$$$$$$
I’m In Both,,,,yes MRNA is sliding today,,, MRNA also has promising opportunity as well! GLTA ,,,,,Still believe we’re on something good here too my friend
My man,,,,, higher highs are up on us!!!!! Let’s get it$$$$$$ I wish u only the best my friend $$$$$$$
Lol,,,, I’ll do my Best
Myself included. Patiently waiting for when Vegas opens..... To DA moon $$$$$$$$$ let’s finish out strong this week!!!!!
Positive vibes bro.... We’re looking good here
Deeze nuts sure show up a lot....... It’s takes big ones to play BIG BY BOARDS according to Dr. Phil... Remember I only post FACTS $$$$$$$$$ Nothing more, nothing less,,,, Dr Phil will listen and advise ALL others on SHORTING themselves SHORT!!!!!!! Here for the LONG HAUL with ACTUAL And TRUE DD $$$$$$$)
GLTA except SHORTY
Brother, We might have to change the name CHEF to ncj167 with all the shares u got!!!!!! I bought 3k worth around 7ish yet u probably have more shares than I do LOL.... I believe but you make me believe in this stock even more$$$$$$$$$)
Just an FYI, researchers have discovered more than different strands of COVID.... your absolutely correct, Vaccine is the answer and I’m betting we’re in the right stock to find the Vaccine my friend. GLTA except Shorty!!!!!
14s printing $$$$$$$
He’s killing me. Just pulled up the video... Crammer is loosing his mind hahahahaha
Waitr Holdings Inc. (Nasdaq: WTRH) ("Waitr" or the "Company"), a leader in on-demand food ordering and delivery, today announced that the Company appointed Charles "Rusty" Holzer and Buford "Buddy" Ortale to the Board of Directors, effective April 23, 2020. Mr. Holzer has been appointed as a member of the Compensation Committee and Mr. Ortale has been appointed as a member of the Audit Committee.
"We are excited to welcome Rusty and Buddy to our Board. They both bring decades of leadership in key areas, such as operations and financing," said Carl Grimstad, Chairman and CEO of Waitr. "We look forward to their valuable perspective and direction as we continue our mission of supporting our restaurants, diners and drivers."
Mr. Holzer is a director of his family-owned real estate company. His responsibilities have included the acquisition, financing, development and management of $1 billion in various real estate transactions; the creation, operation and eventual sale of a nationwide commercial mortgage finance company; as well as the purchase of various non-performing loan packages from the Resolution Trust Company and other financial institutions. Additionally, he supervises the retail division of his family holdings where representative tenants have included Louis Vuitton, Chanel, and Van Cleef and Arpels. Mr. Holzer serves on the board of the Treehouse Real Estate Investment Trust Inc., Equus Foundation, BeaconLight and is a trustee of the Rogal Foundation, a charitable trust, where he is responsible for the selection of investment managers, as well as allocating assets.
Pre market Green... Let’s continue the trend today $$$$$$$
Who knows my friend. Been here a while and seen it go up, then turnaround and fall. One would think the only place to go here on CCL is up!!!!!!
Japan on board with Gilead's remdesivir, approval expected in May
Apr. 27, 2020 9:18 AM ETGilead Sciences, Inc. (GILD)77 Comments
Gilead Sciences (NASDAQ:GILD) perks up 1% premarket on light volume on the heels of a statement from Japan's Prime Minister Shinzo Abe that health authorities intend to approve antiviral remdesivir next month for the treatment of COVID-19.
Once the company files its application, the Japanese government is set to fast track review and approval. A clinical trial there should wind up in this week.
Uhhhhh ohhhhhh $$$$$$$$ More Positive NEWS here!!!!!
Next leg up coming soon!!!!!!!
Exactly, sooner than later.... Can’t hold MRNA back!!!!! It’s too STRONG $$$$$$$$
55 by the end of the week? Anyone thinking I’m too selfish? Chart says WE have a shot!
12s holding strong $$$$$$$$ Keep it up!!!!
I made the list!!!!! Awesome, see, we’re building a relationship. Who knows, maybe you’ll get lucky and I’ll follow you. Need to follow me, I’ll put you on some Winners, not just this stock!!!!!!
I’ll help JUST YOU and No one else $$$$$$$
Let’s work together Dr Phil!!!!!
Ummmmm No.... Zero clue of which side of the fence u are on. Try as u may, your opinions on entry points suck LOL!!!!!! Don’t b upset due to the fact that I have PM from people on your BIG BOY board who agree with statements I make... sorry, not everyone agrees or support s ya. Poor guy, u thought your an ihub legend!!!!!! Long way to go Dr Phil. I’m patient, I’ll ride this wave out too